Financials
Financial Overview
PolyBio is financially sound, balancing revenue and expenses while ensuring that resources are deployed rapidly to advance groundbreaking science. We do not sit on a large endowment; instead, donor funds flow directly into research programs where they can have the greatest impact.
Our financials reflect this commitment: over 98% of expenditures are directed to program work, with less than 2% supporting administration and fundraising. This lean structure underscores our focus on funding discovery, collaboration, and clinical progress.
The charts below provide a clear snapshot of our revenue, expenses, and net assets, as well as the breakdown of program versus administrative costs.
Maximizing Impact Through Strategic Pro-Bono Partnerships
To stretch every philanthropic dollar, PolyBio actively offsets operational and innovation costs through high-value, pro-bono support from mission-aligned experts. These contributions allow us to direct more resources toward scientific discovery. Our pro-bono partners include:
- JPMorgan’s Atwood Group, which provides banking, investment, and complex stock donation infrastructure
- Public Purpose Strategies, led by Michael Brown, City Year co-founder, who serves as a Senior Advisor on nonprofit strategy and organizational growth
- John Galvin, Gordon Brothers executive, who advises on legal frameworks and strategic agreements
Your Money At Work
PolyBio is proud to uphold the highest standards of transparency and accountability. We have earned the Candid/GuideStar Platinum Seal of Transparency and a 4-Star rating from Charity Navigator — the highest recognition for financial health, accountability, and impact.
Independent audits, board oversight, and annual IRS Form 990s ensure that every dollar is stewarded responsibly.
These independent ratings reflect PolyBio’s commitment to stewarding every gift with integrity and ensuring that resources flow where they matter most — fueling scientific breakthroughs that lead to diagnostics and treatments.
